Leuthold Group LLC Acquires 9,447 Shares of Bristol Myers Squibb Company $BMY

Leuthold Group LLC increased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 9.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 107,316 shares of the biopharmaceutical company’s stock after buying an additional 9,447 shares during the quarter. Leuthold Group LLC’s holdings in Bristol Myers Squibb were worth $6,697,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in BMY. Lazard Asset Management LLC boosted its holdings in shares of Bristol Myers Squibb by 23.7% in the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock valued at $116,693,000 after purchasing an additional 368,193 shares during the last quarter. Callan Family Office LLC purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at $3,575,000. Saudi Central Bank grew its stake in shares of Bristol Myers Squibb by 90.2% during the 2nd quarter. Saudi Central Bank now owns 142,922 shares of the biopharmaceutical company’s stock valued at $8,235,000 after buying an additional 67,780 shares during the period. BlackRock Inc. increased its holdings in shares of Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after buying an additional 8,702,106 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its holdings in shares of Bristol Myers Squibb by 17.4% during the 2nd quarter. Envestnet Asset Management Inc. now owns 2,142,754 shares of the biopharmaceutical company’s stock worth $123,465,000 after buying an additional 317,360 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Julia A. Haller sold 3,800 shares of the business’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the transaction, the director directly owned 30,279 shares in the company, valued at approximately $1,916,963.49. The trade was a 11.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.05% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research analysts recently weighed in on BMY shares. Piper Sandler cut their target price on Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating on the stock in a research report on Monday, October 26th. Weiss Ratings raised Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. William Blair restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, October 12th. Royal Bank Of Canada restated a “sector perform” rating on shares of Bristol Myers Squibb in a report on Monday, October 19th. Finally, Cantor Fitzgerald cut their price objective on Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating on the stock in a report on Thursday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $65.46.

Bristol Myers Squibb Trading Up 0.0%

NYSE:BMY opened at $62.16 on Tuesday. The business’s 50-day moving average is $62.25 and its two-hundred day moving average is $60.15. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44. Bristol Myers Squibb Company has a 12 month low of $45.26 and a 12 month high of $68.64. The firm has a market capitalization of $127.06 billion, a PE ratio of 13.78, a price-to-earnings-growth ratio of 0.33 and a beta of 0.20.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The company had revenue of $13.07 billion during the quarter, compared to the consensus estimate of $12.72 billion. During the same quarter in the prior year, the business earned $1.63 earnings per share. The company’s revenue was up 6.9% compared to the same quarter last year. Research analysts predict that Bristol Myers Squibb Company will post 6.45 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.1%. Bristol Myers Squibb’s payout ratio is 55.88%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.